Alzther Industries Provides Update on Amyloid Imaging Study

Alzther Industries will evaluate to include up to 50 additional patients in the study and expects to report final study results during the fourth quarter this year

Seoul, 2016 - Alzther Industries a startup biotechnology company, focused on diseases associated with protein misfolding and which is developing drugs to halt the progression and companion diagnostics for the early detection of Alzheimer’s disease, today reported intermediate results from an exploratory study that examines the correlation between gene expression in blood and brain Amyloid imaging.
In an initial patient population of 100 patients, a correlation between brain amyloid load as measured by brain imaging and gene expression in peripheral blood was established. The primary goal of this exploratory study is to identify a gene expression signature which detects whether an individual has normal or elevated levels of Amyloid in the brain as determined by brain imaging. The subsequent goal is to develop an IVD multivariate index assay test. The study has so far included 100 patients from clinical centers of which 85 were diagnosed with suspected mild cognitive impairment and 15 were healthy controls.
Blood samples were collected and brain Amyloid scans using investigational tracer were performed for all patients. Based on available study data, the preliminary results show a correlation between gene expression in blood and brain imaging results with a specificity of 84% and a sensitivity of 74 % using the brain imaging as the reference.
“This is an exploratory gene signature candidate that requires improvement and verification prior to development into a test for clinical use. We are still awaiting numerical data from the semi-quantitative brain imaging analysis as well as clinical information related to chronic disorders and medication for the study population.” said Sung Hwan-Kuk, Chief Executive Officer of Alzther Industries.

Alzther Industries is a startup biotechnology company supported by various grants and private investors. The funds and our investors support projects with a high potential for future innovations. Alzther Industries is focused on diseases associated with protein misfolding. The company is currently developing drugs to halt the progression of Alzheimer’s disease and companion diagnostics for the early detection of Alzheimer’s disease. Alzther Industries is focused on drug development until phase II clinical studies. The location of the company in Seoul enables the access to experienced experts in the field of drug discovery and development, as well as business development and commercialization.

http://www.alzther.com

Alzther Industries
Tower Palace Three, Tower G, 467 Dogok-dong, Seoul, South Korea
Oskar Jan Vijaya
pr@alzther.com

This release was published on openPR.